Cavidi Revenue

About Cavidi

Precision Diagnostics Welcome to Cavidi, the Swedish biotech firm that is transforming the field of biomarker detection with our groundbreaking solution, Exazym® — the world’s first add-on reagent to deliver ultra-sensitive detection of low-abundance biomarkers using standard immunoassay workflows. Our Vision and Mission At Cavidi, we envision a world where every individual has access to healthcare that's personalized, preventative, and precise. To accomplish that, our mission is to enable researchers like you by providing greater access to precision diagnostics. We are out to democratize detection by establishing Binding Oligo Ladder Detection (BOLD) as the world’s go-to ultra-sensitive immunoassay amplification technology by 2030. That is why we encourage you to take advantage of this breakthrough technology to achieve new limits of detection in your research. Exazym®: Ultra-Sensitive, Easy to Implement, Quick Results Any advanced diagnostics need to offer cutting-edge sensitivity and selectivity. Exazym® is no exception. Compared to standard ELISA, it delivers up to 100x the signal amplification and a 50x lower limit of detection. At Cavidi, we see that achievement as a starting point. Only after a test has achieved both high accuracy and high access will it get top marks in our book. Exazym® embodies this standard. It is a RUO reagent kit that can be added to any standard immunoassay workflow using standard laboratory equipment, previously optimized antibody pairs, and established testing protocols. This enables rapid implementation without the need for extensive revalidation or new capital equipment. Exazym® adds just one additional step to your workflow that, in most cases, requires less than 30 minutes once the protocol is optimized to the improved Limit of Detection (LoD).

View contact profiles from Cavidi